News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Patterson Matthew R
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/15/2023 |
4
| Patterson Matthew R (Director) has filed a Form 4 on Homology Medicines, Inc.|
Txns:
| Granted 23,000 options to buy
@ $1.03, valued at
$23.7k
|
|
| 06/02/2023 |
4
| Patterson Matthew R (Director) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Granted 30,000 options to buy
@ $4.79, valued at
$143.7k
|
|
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2022 |
4
| Patterson Matthew R (Director) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Granted 16,911 options to buy
@ $4.26, valued at
$72k
|
|
| 06/22/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/09/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/04/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 10/20/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/13/2020 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/12/2020 |
4
| Patterson Matthew R (Director) has filed a Form 4 on Homology Medicines, Inc.|
Txns:
| Granted 18,000 options to buy
@ $16.32, valued at
$293.8k
|
|
| 01/15/2020 |
4
| Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 261,458 shares
@ $60, valued at
$15.7M
Unknown transaction of 171,814 shares
@ $60, valued at
$10.3M
Disposed/sold 143,569 options to buy
@ $9.4988, valued at
$1.4M
Disposed/sold 188,334 options to buy
@ $15.26, valued at
$2.9M
Disposed/sold 225,000 options to buy
@ $27.39, valued at
$6.2M
Disposed/sold 177,450 options to buy
@ $24.74, valued at
$4.4M
|
|
| 01/10/2020 |
4
| Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Gifted 12,500 shares
@ $0
Exercised 64,751 options to buy
@ $0.78, valued at
$50.5k
Exercised 74,297 options to buy
@ $2.19, valued at
$162.7k
Exercised 11,824 options to buy
@ $9.5, valued at
$112.3k
Exercised 11,666 options to buy
@ $15.26, valued at
$178k
|
|
| 12/09/2019 |
4
| Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 1,974 shares
@ $59.21, valued at
$116.9k
|
|
| 11/12/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/09/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/14/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/10/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/07/2019 |
4
| Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 3,332 shares
@ $37.31, valued at
$124.3k
|
|
| 02/27/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/08/2019 |
4
| Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Granted 63,700 shares
@ $0
Granted 177,450 options to buy
@ $24.74, valued at
$4.4M
|
|
| 12/10/2018 |
4
| Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Exercised 40,000 options to buy
@ $0.78, valued at
$31.2k
|
|
| 10/02/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/24/2018 |
4
| Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Exercised 15,000 options to buy
@ $0.78, valued at
$11.7k
|
|
| 09/20/2018 |
4
| Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Sold 12,952 shares
@ $40, valued at
$518.1k
Exercised 12,952 options to buy
@ $2.19, valued at
$28.4k
|
|
| 07/05/2018 |
4
| Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Sold 19,599 shares
@ $38.3282, valued at
$751.2k
Sold 1,401 shares
@ $38.7793, valued at
$54.3k
Sold 26,901 shares
@ $40.0528, valued at
$1.1M
Sold 23,147 shares
@ $40.042, valued at
$926.9k
Exercised 19,599 options to buy
@ $0.78, valued at
$15.3k
Exercised 1,401 options to buy
@ $0.78, valued at
$1.1k
Exercised 26,901 options to buy
@ $0.78, valued at
$21k
Exercised 23,147 options to buy
@ $0.78, valued at
$18.1k
|
|
| 05/23/2018 |
4
| Patterson Matthew R (President & CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Sold 13,600 shares
@ $38.08, valued at
$517.9k
Sold 6,700 shares
@ $38.3, valued at
$256.6k
Exercised 20,300 options to buy
@ $0.78, valued at
$15.8k
|
|
| 04/04/2018 |
4
| Patterson Matthew R (President & CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Sold 700 shares
@ $30.0129, valued at
$21k
Exercised 700 options to buy
@ $0.78, valued at
$546 |
|
| 03/29/2018 |
4
| Patterson Matthew R (Director) has filed a Form 4 on Homology Medicines, Inc.|
Txns:
| Granted 8,360 options to buy
@ $16, valued at
$133.8k
|
|
| 03/27/2018 |
3
| Patterson Matthew R (Director) has filed a Form 3 on Homology Medicines, Inc. |
| 11/17/2017 |
4
| Patterson Matthew R (President & CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Granted 225,000 options to buy
@ $27.39, valued at
$6.2M
|
|
| 10/04/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/19/2017 |
4
| Patterson Matthew R (President & CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Sold 1,542 shares
@ $25.0006, valued at
$38.6k
Sold 8,458 shares
@ $25.0662, valued at
$212k
Exercised 1,542 options to buy
@ $0.78, valued at
$1.2k
Exercised 8,458 options to buy
@ $0.78, valued at
$6.6k
|
|
| 07/14/2017 |
4
| Patterson Matthew R (President & CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Sold 2,850 shares
@ $20.0025, valued at
$57k
Sold 12,150 shares
@ $20.0043, valued at
$243.1k
|
|
| 01/27/2017 |
4
| Patterson Matthew R (President & CEO) has filed a Form 4 on Audentes Therapeutics, Inc. |
|
|
|